Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- Thermo Fisher Scientific has opened a new Cryo-Electron Microscopy Drug Discovery Center in South San Francisco to provide pharmaceutical and biotechnology companies with advanced cryo-EM technologies for accelerated drug development. - Structure-guided drugs developed using cryo-EM technology demonstrate more than twice the clinical success rate in half the preclinical time and at half the cost compared to industry standards. - The new center builds on the success of the UK Pharmaceutical Cryo-EM Consortium established in 2016, extending this collaborative approach to the North American market with founding customer members. - Located in Oyster Point, the center combines state-of-the-art cryo-EM instrumentation with collaborative scientific environments to expedite the path from drug discovery to development.
- Thermo Fisher Scientific announced a strategic collaboration with Datavant to integrate privacy-preserving tokenization technology across its PPD clinical research business, enabling secure linkage of patient-level data from over 350 real-world data partners and 80,000 US hospitals and clinics. - The partnership aims to enhance real-world data enrichment of randomized clinical trials and improve connectivity across PPD CorEvitas Clinical Registries and PPD Evidera solutions through encrypted tokenization and secure data linkage capabilities. - The collaboration is designed to help pharmaceutical and biotech sponsors generate stronger evidence faster by providing enhanced linked patient data and advanced analytics to improve study design, patient recruitment strategies, and accelerate evidence generation. - This partnership builds on Thermo Fisher's broader digital transformation strategy, complementing recent investments including a strategic collaboration with OpenAI to embed artificial intelligence across drug development processes.
- Thermo Fisher Scientific introduces Accelerator Drug Development, an integrated CDMO and CRO solution designed to streamline pharmaceutical development from early research to commercialization. - The platform addresses critical industry challenges including escalating R&D costs estimated at $1.3-2.8 billion per approved drug and inefficiencies caused by fragmented vendor relationships. - The integrated approach provides single-vendor accountability across clinical research, manufacturing, and supply chain operations, targeting both small biotech companies and large pharmaceutical organizations. - Clinical trials account for 70% of total R&D expenditures, making coordination improvements in trial design, execution, and supply chain management key cost reduction opportunities.
- Thermo Fisher Scientific is acquiring clinical trial data management company Clario Holdings for approximately $10 billion in an all-cash transaction expected to close by mid-2026. - The acquisition will enhance Thermo Fisher's digital and AI capabilities in clinical research, enabling pharmaceutical and biotech customers to accelerate drug development with deeper clinical insights. - Clario's differentiated digital endpoint platform and proprietary AI tools will complement Thermo Fisher's existing clinical research offerings, creating meaningful benefits for customers conducting increasingly complex clinical trials. - The transaction is expected to deliver attractive financial returns with double-digit internal rate of return, adding $0.45 adjusted EPS in the first year and approximately $175 million in synergies by year five.
- Thermo Fisher Scientific, a $40 billion life sciences company, has announced a strategic partnership with OpenAI to integrate artificial intelligence across pharmaceutical research and development operations. - The collaboration will initially focus on Thermo Fisher's PPD clinical research business, using AI to shorten trial cycles and improve decision-making in early-stage drug development. - OpenAI's technology will be embedded into Thermo Fisher's Accelerator Drug Development solution, covering the full drug pipeline from discovery through Phase I-III research to manufacturing and commercialization. - The partnership aims to reduce the cost and time required to bring new medicines to market while helping identify therapies unlikely to succeed more quickly.
- Thermo Fisher Scientific's PPD clinical research business has established a new R&D partnership with AstraZeneca BioVentureHub in Gothenburg, Sweden, focusing on collaborative innovation in life sciences. - A dedicated Thermo Fisher team will co-locate with AstraZeneca scientists to work on R&D projects initially targeting chromatography, molecular genomics, and proteomics technologies. - The partnership is part of Gothenburg's growing innovation ecosystem, which will include Thermo Fisher's new state-of-the-art bioanalytical laboratory expected to begin operations in March 2026. - The collaboration aims to strengthen the life science ecosystem and provide cutting-edge technologies for emerging biotech companies and academic groups working on pharmaceutical development.
- Resonant Clinical Solutions, a global provider of clinical trial services, has appointed Dr. Christophe Berthoux as Chief Executive Officer effective immediately. - Berthoux brings over three decades of pharmaceutical services leadership experience, including CEO roles at NAMSA, Synexus, and CitoxLab. - The appointment follows Audax Private Equity's acquisition of Resonant from Avantor in 2024, marking a strategic milestone in the company's evolution. - Resonant operates with over 850 employees across the US, UK, and Europe, providing clinical trial kitting, equipment services, and biorepository management.
• Selkirk Pharma appoints former AstraZeneca executive Colleen Dixon as CEO, bringing extensive leadership experience from major pharmaceutical companies to strengthen their injectable drugs manufacturing operations. • Multiple CDMOs and clinical trial technology companies enhance their executive teams, with Oxford Biomedica and Veranova adding new C-suite leaders to drive strategic growth. • Several CROs including MMS, Metrion Biosciences, and Catawba Research bolster their commercial leadership, reflecting industry-wide focus on business development and market expansion.
